Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)

Clinical trial NCT04040322 · COMPLETED

Trial details

NCT number: NCT04040322
Sponsor: Civi Biopharma, Inc.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Raynaud's Phenomenon Secondary to Systemic Sclerosis

Start date: 2019-10-14
Primary completion: 2021-06-09
Enrollment: 198

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.